Biotech | August 02, 2021
Bharat Biotech gets WHO prequalification for ROTAVAC 5D
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Financial support is being provided as a grant from the Government of India
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
The Phase 2 study of Sputnik V was conducted on 100 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India.
Subscribe To Our Newsletter & Stay Updated
